Skip to main content


The Board of Administration of AB-Biotics, which is traded on the Alternative Stock Market (MAB), approved the decision to propose a capital increase to start up their international expansion plan at their next General Shareholders Meeting. With five products on the market and several more in advanced stages of development, the company aims to reinforce their commercial activity and have a direct presence in high-potential countries like the United States, the United Kingdom, Germany, France, Turkey, Mexico and Brazil.

The capital raised will go mainly to market expansion of Neurofarmagen, a line of drugs for personalized medicine. In early 2010, AB-Biotics launched Neurofarmagen Psiquiatria, a DNA test that uses saliva samples to determine patients’ predisposition to respond to the most common drugs used to treat diseases like depression, schizophrenia, bipolar disorder and epilepsy.  In October 2010, they introduced Neurofarmagen TDAH, a genetic test that determines patients’ response to the main drugs used to treat attention deficit disorder and hyperactivity and helps gauge their risk for developing this disorder in the future (product licensed to Laboratoris Rubió). And this past January, they launched Neurofarmagen Epilèpsia, which can predict how patients will respond to the most common drugs for treating epilepsy.

AB-Biotics participated in the top global biotech convention, BIO Washington, last June with the delegation of Catalan companies led by Biocat. They took advantage of this event to present these new products internationally, as well as AB-LIFE, a functional ingredient to reduce cholesterol levels, and AB-I3.1, a probiotic to improve quality of life for patients with irritable bowel syndrome.

This Catalan company’s income in 2010 totaled €3.6 millions, 74% more than the previous year. They employ a staff of 51 workers.

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.